Herantis Pharma Plc Company release
The Shareholders' Nomination Committee presents the following proposals to the Annual General Meeting to be held on
Proposal on the number of the members and election of the members of the Board of Directors
The Shareholders' Nomination Committee proposes that the number of members of the Board of Directors shall be five (5).
The Shareholders' Nomination Committee further proposes that of the current members of the Board of Directors,
Proposal on the remuneration of the members of the Board of Directors and reimbursement of travel expenses
The Shareholders' Nomination Committee proposes that the remuneration of the Board of Directors shall be as follows:
- The remuneration payable to the members of the Board of Directors shall be
EUR 18,000 annually for each member of the Board except for the Chairman of the Board who shall be paidEUR 36,000 annually. -
The Chairman of the Audit Committee shall receive a fixed annual fee of
EUR 8,000 and each member of the Audit Committee a fixed annual fee ofEUR 4,000 . -
The Chairman of the Remuneration Committee shall receive a fixed annual fee of
EUR 4,000 and each member of the Remuneration Committee a fixed annual fee ofEUR 2,000 . - Board members are also reimbursed reasonable travel expenses related to the duties of the Board of Directors.
Composition of the Shareholders' Nomination Committee
The Shareholders' Nomination Committee was established by Herantis Pharma's Annual General Meeting on
In
- Kyösti Kakkonen, representing Joensuun Kauppa ja
Kone Oy (Chairman); -
Pia Gisgård, representing
Swedbank Robur ; - Timo Syrjälä, representing himself and Acme Investments SPF S.à.r.l.; and
Timo Veromaa , the Chairman of Herantis Pharma's Board of Directors.
For more information, please contact:
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email: ir@herantis.com
---------------------------------
Certified Advisor:
Company website: www.herantis.com
About
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. As previously announced by Herantis,
https://news.cision.com/herantis-pharma-oyj/r/proposals-of-the-shareholders--nomination-committee-to-herantis-pharma-plc-s-annual-general-meeting-,c3700620
https://mb.cision.com/Main/18884/3700620/1793447.pdf
(c) 2023 Cision. All rights reserved., source